AR098686A2 - Formas de dosificación de bifosfonatos - Google Patents
Formas de dosificación de bifosfonatosInfo
- Publication number
- AR098686A2 AR098686A2 ARP140104583A ARP140104583A AR098686A2 AR 098686 A2 AR098686 A2 AR 098686A2 AR P140104583 A ARP140104583 A AR P140104583A AR P140104583 A ARP140104583 A AR P140104583A AR 098686 A2 AR098686 A2 AR 098686A2
- Authority
- AR
- Argentina
- Prior art keywords
- release
- salts
- edta
- bisphosphonate
- time
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 229940122361 Bisphosphonate Drugs 0.000 abstract 3
- 150000004663 bisphosphonates Chemical class 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000030136 gastric emptying Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 abstract 1
- 229940089617 risedronate Drugs 0.000 abstract 1
- 239000002195 soluble material Substances 0.000 abstract 1
- 230000036962 time dependent Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Reivindicación 1: Una forma de dosificación oral caracterizada porque comprende: (a) entre 1 mg y 500 mg de un bifosfonato seleccionado del grupo formado por risedronato, y sus ácidos, sales y ésteres; (b) de 10 mg a 500 mg de ácido etilendiaminatetraacético (EDTA) o sus sales; y (c) un medio para la liberación retardada para liberar el bisfosfonato y el EDTA o sus sales en el tracto gastrointestinal, en donde el medio de liberación retardada se selecciona del grupo formado por una formulación de liberación dependiente del tiempo que comprende un dispositivo dependiente del tiempo que tiene un tiempo de transito predeterminado después de vaciamiento gástrico para liberar el bifosfonato, EDTA o sus sales en el tracto gastrointestinal inferior, recubrimientos de hidrogel que se degradan con el tiempo para liberar el contenido de un comprimido, o ambos, una formulación de liberación provocada por una enzima bacteriana que comprende un revestimiento de un material soluble en ácido, que se recubre luego con un recubrimiento entérico, y cualquier combinación de los mismos, en donde la absorción de la forma de dosificación oral esta dentro del 50% de la absorción en ayunas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57388104P | 2004-05-24 | 2004-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098686A2 true AR098686A2 (es) | 2016-06-08 |
Family
ID=35355642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101507A AR049022A1 (es) | 2004-05-24 | 2005-04-15 | Formas de dosificacion de bifosfonatos |
| ARP140104583A AR098686A2 (es) | 2004-05-24 | 2014-12-10 | Formas de dosificación de bifosfonatos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101507A AR049022A1 (es) | 2004-05-24 | 2005-04-15 | Formas de dosificacion de bifosfonatos |
Country Status (31)
| Country | Link |
|---|---|
| EP (3) | EP1753395B1 (es) |
| JP (2) | JP4605221B2 (es) |
| KR (5) | KR101388777B1 (es) |
| CN (2) | CN1956706A (es) |
| AR (2) | AR049022A1 (es) |
| AT (1) | ATE475412T1 (es) |
| AU (2) | AU2005247299B2 (es) |
| BR (1) | BRPI0511530A (es) |
| CA (1) | CA2566798A1 (es) |
| CY (2) | CY1111259T1 (es) |
| DE (1) | DE602005022578D1 (es) |
| DK (2) | DK1753395T3 (es) |
| ES (3) | ES2349584T3 (es) |
| HR (1) | HRP20100583T1 (es) |
| HU (1) | HUE059143T2 (es) |
| IL (1) | IL179090A (es) |
| MA (1) | MA28657B1 (es) |
| MX (1) | MXPA06013575A (es) |
| MY (1) | MY144704A (es) |
| NO (1) | NO20065969L (es) |
| NZ (2) | NZ587774A (es) |
| PE (1) | PE20060256A1 (es) |
| PL (2) | PL2283825T3 (es) |
| PT (3) | PT1753395E (es) |
| RS (1) | RS51562B (es) |
| RU (1) | RU2359678C2 (es) |
| SI (1) | SI1753395T1 (es) |
| SM (1) | SMP200600038B (es) |
| TW (2) | TWI351285B (es) |
| WO (1) | WO2005115331A2 (es) |
| ZA (1) | ZA200609446B (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| AU2011218625B2 (en) * | 2004-05-24 | 2014-03-20 | Theramex HQ UK Limited | Dosage forms of risedronate |
| US7645459B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| JP2008533173A (ja) | 2005-03-17 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ビスホスホネート組成物 |
| CA2622322A1 (en) * | 2005-09-16 | 2007-03-22 | Selamine Ltd | Bisphosphonate formulation |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| ES2426445T3 (es) * | 2006-04-07 | 2013-10-23 | Merrion Research Iii Limited | Forma de dosificación oral sólida que contiene un potenciador |
| CN101530415A (zh) * | 2008-03-10 | 2009-09-16 | 北京德众万全医药科技有限公司 | 一种含有双膦酸盐的药物组合物及其制备方法 |
| KR20110007614A (ko) | 2008-05-07 | 2011-01-24 | 메리온 리서치 Ⅲ 리미티드 | ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법 |
| WO2010014765A1 (en) * | 2008-07-31 | 2010-02-04 | Warner Chilcott Company, Llc | Low dosage forms of risedronate or its salts |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| HRP20171755T1 (hr) | 2009-07-31 | 2017-12-29 | Grünenthal GmbH | Postupak kristalizacije i biološka raspoloživost |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| FR2954320B1 (fr) | 2009-12-17 | 2012-06-15 | Cll Pharma | Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels |
| SG183272A1 (en) * | 2010-02-10 | 2012-09-27 | Fujifilm Ri Pharma Co Ltd | Radioactive metal-labeled anti-cadherin antibody |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| WO2011122524A1 (ja) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
| CN102885759A (zh) * | 2011-07-20 | 2013-01-23 | 杭州赛利药物研究所有限公司 | 利塞膦酸钠延释制剂及其制备方法 |
| KR101324425B1 (ko) * | 2011-07-22 | 2013-11-01 | 동아에스티 주식회사 | 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제 |
| KR20130014376A (ko) * | 2011-07-28 | 2013-02-07 | 주식회사유한양행 | 비스포스폰산 또는 그의 염을 함유하는 경구용 약학 조성물 |
| EP2572736A1 (en) * | 2011-09-23 | 2013-03-27 | Spago Imaging AB | Nanostructures comprising manganese |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
| US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
| US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
| US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| KR20150035597A (ko) * | 2012-05-14 | 2015-04-06 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 염증성 통증 및 관련 병태의 경감을 위한, 졸레드론산 또는 관련 화합물을 포함하는 조성물 |
| US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
| US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
| US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
| US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| CN103784405B (zh) * | 2012-11-02 | 2015-07-08 | 沈阳药科大学 | 一种改善利塞膦酸钠口服生物利用度的制剂及其制备方法 |
| ES2975708T3 (es) | 2015-01-29 | 2024-07-12 | Novo Nordisk As | Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico |
| RU2609871C1 (ru) * | 2015-08-10 | 2017-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Противоопухолевое средство |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN109200020A (zh) * | 2017-07-07 | 2019-01-15 | 长春海悦药业股份有限公司 | 一种埃索美拉唑镁的药物组合物 |
| JPWO2023249087A1 (es) * | 2022-06-24 | 2023-12-28 | ||
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA777769A (en) | 1963-03-18 | 1968-02-06 | H. Roy Clarence | Substituted methylene diphosphonic acid compounds and detergent compositions |
| IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| US4639338A (en) | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| US4812311A (en) | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| IL77243A (en) | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| WO1993009785A1 (en) * | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| WO1996039149A1 (en) | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
| CA2221844A1 (en) | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Disodium alendronate formulations |
| ES2210529T3 (es) * | 1996-05-17 | 2004-07-01 | MERCK & CO., INC. | Formulacion de bisfosfonato efervescente. |
| SE9703691D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
| US6290938B1 (en) * | 1998-07-30 | 2001-09-18 | The Procter & Gamble Company | Sunscreen compositions |
| US6008207A (en) | 1998-08-13 | 1999-12-28 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
| PL346347A1 (en) | 1998-08-27 | 2002-02-11 | Teva Pharma | Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof |
| SE9901272D0 (sv) * | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| WO2001032185A1 (en) * | 1999-11-02 | 2001-05-10 | Cipla Ltd. | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof |
| US6410520B2 (en) | 2000-02-01 | 2002-06-25 | The Procter & Gamble Company | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| HUP0303700A3 (en) * | 2000-07-17 | 2006-07-28 | Astellas Pharma Inc Chuo Ku | Pharmaceutical composition improved in peroral absorbability |
| BR0106601A (pt) | 2001-12-21 | 2003-09-09 | Libbs Farmaceutica Ltda | Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato |
| EP1455796A1 (en) * | 2001-12-21 | 2004-09-15 | The Procter & Gamble Company | Method for the treatment of bone disorders |
-
2005
- 2005-04-14 CN CNA2005800160870A patent/CN1956706A/zh active Pending
- 2005-04-14 NZ NZ587774A patent/NZ587774A/en not_active IP Right Cessation
- 2005-04-14 AT AT05735411T patent/ATE475412T1/de active
- 2005-04-14 EP EP05735411A patent/EP1753395B1/en not_active Revoked
- 2005-04-14 KR KR1020117002644A patent/KR101388777B1/ko not_active Expired - Lifetime
- 2005-04-14 HR HR20100583T patent/HRP20100583T1/hr unknown
- 2005-04-14 PL PL10011938.7T patent/PL2283825T3/pl unknown
- 2005-04-14 DE DE602005022578T patent/DE602005022578D1/de not_active Expired - Lifetime
- 2005-04-14 KR KR1020137013818A patent/KR20130063041A/ko not_active Ceased
- 2005-04-14 CA CA002566798A patent/CA2566798A1/en not_active Abandoned
- 2005-04-14 SI SI200531116T patent/SI1753395T1/sl unknown
- 2005-04-14 HU HUE10011938A patent/HUE059143T2/hu unknown
- 2005-04-14 RS RS20100458A patent/RS51562B/sr unknown
- 2005-04-14 ES ES05735411T patent/ES2349584T3/es not_active Expired - Lifetime
- 2005-04-14 MX MXPA06013575A patent/MXPA06013575A/es active IP Right Grant
- 2005-04-14 JP JP2007515076A patent/JP4605221B2/ja not_active Expired - Fee Related
- 2005-04-14 ES ES10011938T patent/ES2921141T3/es not_active Expired - Lifetime
- 2005-04-14 PT PT05735411T patent/PT1753395E/pt unknown
- 2005-04-14 MY MYPI20051652A patent/MY144704A/en unknown
- 2005-04-14 PL PL05735411T patent/PL1753395T3/pl unknown
- 2005-04-14 KR KR1020087020470A patent/KR20080083068A/ko not_active Ceased
- 2005-04-14 EP EP10006061.5A patent/EP2269584B1/en not_active Expired - Lifetime
- 2005-04-14 DK DK05735411.0T patent/DK1753395T3/da active
- 2005-04-14 ES ES10006061T patent/ES2921364T3/es not_active Expired - Lifetime
- 2005-04-14 KR KR1020127023504A patent/KR101411117B1/ko not_active Expired - Fee Related
- 2005-04-14 SM SM200600038T patent/SMP200600038B/it unknown
- 2005-04-14 DK DK10011938.7T patent/DK2283825T3/da active
- 2005-04-14 KR KR1020067024712A patent/KR20070015596A/ko not_active Ceased
- 2005-04-14 WO PCT/US2005/012537 patent/WO2005115331A2/en not_active Ceased
- 2005-04-14 CN CN2011101588498A patent/CN102225047B/zh not_active Expired - Fee Related
- 2005-04-14 NZ NZ551118A patent/NZ551118A/en not_active IP Right Cessation
- 2005-04-14 BR BRPI0511530-2A patent/BRPI0511530A/pt not_active Application Discontinuation
- 2005-04-14 AU AU2005247299A patent/AU2005247299B2/en not_active Ceased
- 2005-04-14 PT PT100060615T patent/PT2269584T/pt unknown
- 2005-04-14 RU RU2006140888/15A patent/RU2359678C2/ru not_active IP Right Cessation
- 2005-04-14 EP EP10011938.7A patent/EP2283825B1/en not_active Expired - Lifetime
- 2005-04-14 PT PT100119387T patent/PT2283825T/pt unknown
- 2005-04-15 PE PE2005000423A patent/PE20060256A1/es not_active Application Discontinuation
- 2005-04-15 TW TW094112107A patent/TWI351285B/zh not_active IP Right Cessation
- 2005-04-15 TW TW100124958A patent/TW201138783A/zh unknown
- 2005-04-15 AR ARP050101507A patent/AR049022A1/es not_active Application Discontinuation
-
2006
- 2006-11-07 IL IL179090A patent/IL179090A/en active IP Right Grant
- 2006-11-14 ZA ZA200609446A patent/ZA200609446B/xx unknown
- 2006-12-08 MA MA29522A patent/MA28657B1/fr unknown
- 2006-12-20 NO NO20065969A patent/NO20065969L/no not_active Application Discontinuation
-
2008
- 2008-06-16 AU AU2008202652A patent/AU2008202652B2/en not_active Expired
-
2010
- 2010-08-10 JP JP2010179574A patent/JP2010275319A/ja active Pending
- 2010-10-27 CY CY20101100978T patent/CY1111259T1/el unknown
-
2014
- 2014-12-10 AR ARP140104583A patent/AR098686A2/es not_active Application Discontinuation
-
2022
- 2022-07-12 CY CY20221100478T patent/CY1125501T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098686A2 (es) | Formas de dosificación de bifosfonatos | |
| JOP20200145A1 (ar) | تركيبة عقار ذو إطلاق متأخر | |
| AR085547A1 (es) | Composicion compleja oral que comprende ester del acido graso omega-3 y un inhibidor de la hmg-coa reductasa | |
| ATE463593T1 (de) | Dampfphasen-korrosionsinhibitoren und verfahren zu deren herstellung | |
| DOP2010000307A (es) | Metodos y composiciones liquidas de limpieza | |
| UY31698A (es) | Preparacion solida de desintegracion oral | |
| AR076628A1 (es) | Carbohidratos | |
| ECSP088490A (es) | Forma farmacéutica oral que contiene como principios activos un inhibidor de la bomba de protones junto con ácido acetilsalicílico | |
| WO2011101866A3 (en) | Gastric retention formulation containing baclofen | |
| MX382146B (es) | Formulacion de farmaco de liberacion retardada. | |
| AR058332A1 (es) | Composicion farmaceutica dispersable oralmente para la administracion mucoso - oral o sublingual de agomelatina | |
| ATE457719T2 (de) | Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel | |
| ES2555306T3 (es) | Procedimiento de envoltura de productos alimentarios | |
| ECSP11011286A (es) | Formulaciones orales sólidas de una pirido-pirimidinona | |
| EP1998365A4 (en) | ELECTROSTATIC TIGHTENING DEVICE FOR A GLASS SUBSTRATE AND METHOD FOR ATTACHING AND RELEASING SUCH A GLASS SUBSTRATE | |
| AR019715A1 (es) | Sistema terapeutico percutaneo, que contiene hormonas e inhibidores de cristalizacion | |
| DOP2006000168A (es) | Dispositivos transdérmicos de liberación de fármaco que contienen drospirenona y métodos de liberación de los mismos | |
| AR101481A1 (es) | Prevención y remoción de manchas dentales | |
| GB2487130B (en) | Bilayer systems including a polydimethylglutarimide-based bottom layer and compositions thereof | |
| ATE418969T1 (de) | Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung | |
| AR060733A1 (es) | Proceso para la precipitacion y el aislamiento de compuestos de 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen los mismos | |
| PH12017502369A1 (en) | A delayed release drug formulation | |
| ATE542237T1 (de) | Verfahren zur übertragung mit einem ferroelektrischen substrat | |
| SV2009003143A (es) | Formulacion farmacologica acuosa de acido 4- [((4-carboxibutil)- {2-[(4-fenetil-bencil)oxi] -fenetil} amino)mentil]benzoico | |
| PL377706A1 (pl) | Kompozycja farmaceutyczna zawierająca kwas alendronowy, jego sole lub estry oraz sposób jej otrzymywania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |